BOCA RATON, Fla.–(BUSINESS WIRE)–SurGenTec®, a leading innovator in minimally invasive orthopedic and spine surgery solutions, is proud to announce the launch of its new TiLINK®-INSITE™ Sacroiliac Joint Fusion System. The system—now available in a sterile, surgery-ready kit—has already been successfully utilized in initial procedures performed across multiple U.S. sites, receiving strong endorsements from physicians.
The INSITE™ kit features a complete set of single-use, sterile instruments paired with an advanced 3D-printed titanium implant. By eliminating the need for traditional sterilization—which can be costly, time-consuming, and carry inherent risks—this all-in-one sterile solution streamlines surgical preparation and improves procedural efficiency. Designed to reduce infection risk and support a minimally invasive approach, the INSITE™ system offers a cost-effective, surgery-ready option for physicians seeking to deliver long-term relief to patients suffering from SI joint dysfunction.
The INSITE™ implant incorporates proprietary nano-surface technology to encourage bone-on-implant growth and promote lasting biologic fixation. A large central graft window enables significant graft volume for robust osteointegration across the ilium and sacrum. The implant’s integrated trellis architecture delivers both structural strength and open porosity to support bone in-growth throughout the device. Threaded insertion eliminates the need for malleting, minimizing surgical trauma and enabling a smooth, controlled placement through a single small incision—roughly the size of a quarter.
“INSITE™ has been engineered with both patients and physicians in mind,” said Travis Greenhalgh, CEO of SurGenTec®. “We’re offering a system that not only simplifies the procedure with a complete, sterile, single-use kit but also provides the greatest opportunity for long-term fusion. The strong feedback we’ve received from early adopters validates our approach and furthers our mission to transform care in SI joint fusion.”
INSITE™ expands SurGenTec®’s growing sacroiliac joint fusion portfolio, which includes:
- TiLINK®–P™: posterior SI fusion device known for its controlled compression and transfixation
- TiLINK®-L™: Implant designed for immediate fixation via an oblique or lateral approach.
“With the addition of INSITE™, we now offer surgeons a full spectrum of options for SI joint fusion,” added Greenhalgh.
SurGenTec® plans to make its entire SI joint fusion portfolio available in sterile kit formats by the end of 2025. The company will showcase INSITE™ along with other flagship technologies this week at the ASPN Pain and Neuroscience Conference in Miami, Florida.
Headquartered in Boca Raton, Florida, SurGenTec® is dedicated to developing and manufacturing cutting-edge technologies for orthopedic and neurosurgical applications. With a robust innovation pipeline, the company is set to release several new products through the remainder of 2025.
Contacts
Customer Service
(561) 990 7882
customerservice@surgentec.com